AstraZeneca Plc (NASDAQ:AZN) shares are trading higher Friday after the drugmaker reported third-quarter results that topped analyst estimates and reaffirmed its full-year guidance.

What To Know: AstraZeneca reported third-quarter core earnings of $2.79 per share, beating the consensus estimate of $2.59. Total revenue of $16.21 billion beat the $16.03 billion estimate and rose 7% year-over-year at constant exchange rates.

For the first nine months of the year, total revenue increased 7% and core earnings per share rose 14%, both at constant exchange rates, with double-digit growth in oncology, respiratory and immunology and rare disease offsetting loss of exclusivity for Farxiga and Brilinta.

The company reaffirmed its 2026 guidance, expecting total revenue to grow by a mid-to-high single-digit percentage and core EPS to grow by a low double-digit percentage at constant exchange rates.

AstraZeneca also reported 12 positive Phase III readouts so far this year and 47 approvals in major regions since its fourth-quarter 2025 results, including first approvals for four new medicines.

“Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars,” CEO Pascal Soriot said.

AZN Price Action: AstraZeneca shares were up 3.23% at $174.99 in premarket trading Friday, according to Benzinga Pro data.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.